retatrutide obesity clinical trial results Lilly's triple agonist achieves 16.8% weight loss in phase 3 Incretin triple agonist retatrutide (LY3437943)

While the Virginia Tech researchers zeroed in on how GLP-1 drugs might alter alcohol absorption, companies in the behavior-change space may have a leg up on what (potentially) comes next

Injection Sites Inject subcutaneously into the abdomen, front of thigh, or upper arm

In controlled in-vitro and analytical systems, LC526 (Lipo C 526) supports study of mitochondrial long-chain fatty acid transport via the L-Carnitine/CPT shuttle, NAD/NADH ratio dynamics through included NADH, hepatic lipotropic signaling via the MIC complex (Methionine, Inositol, Choline), and one-carbon methylation biology through Methionine and Vitamin B12 cofactors

Sanger GJ, Andrews PL